OPN 9840
Alternative Names: OPN-9840Latest Information Update: 17 Apr 2024
At a glance
- Originator Plexxikon
- Developer Opna Bio
- Class Antineoplastics; Small molecules
- Mechanism of Action TEA domain transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Malignant-mesothelioma
Most Recent Events
- 10 Apr 2024 Preclinical trials in Malignant mesothelioma in Switzerland (PO)
- 05 Apr 2024 Adverse events and pharmacodynamics data from preclinical studies in Malignant mesothelioma presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 02 Feb 2024 OPN 9840 is available for licensing as of 24 Jan 2024. https://www.opnabio.com/pipeline/